Endo (ENDP) Target Raised to $110 at Piper Jaffray as Physician Survey Bodes Well For Belbuca Uptake
Tweet Send to a Friend
Piper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Endo International plc (NASDAQ: ENDP) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE